Skip to content
WeighLab
Menu
Ranked #9 · Grade B−Editorial review

Henry Meds review

A transparent flat-fee pioneer — the pricing is clean and modelable, but it now sits at the higher end, so the value per dollar has slipped.

Visit Henry Meds Editorial review — no commercial relationship.
Semaglutide
$249/mo
Tirzepatide
$349/mo
Coverage
Multi-state
Brand-name
Compounded only

Semaglutide · modeled / year

$2,988

Tirzepatide · modeled / year

$4,188

The Index scorecard

Henry Meds scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month74/100
Price Transparency86/100
Nationwide Access84/100
Formulation Options80/100
Clinical Oversight83/100
Contract Flexibility84/100

Where the value is

  • Simple, transparent flat-fee model that's easy to model
  • Well-established brand
  • Both molecules disclosed

The tradeoffs

  • Higher per-month cost than many newer entrants weakens value
  • Compounded only

The bottom line

Best for: People who want a simple, well-known flat-fee program and will pay a premium for the brand. A transparent flat-fee pioneer — the pricing is clean and modelable, but it now sits at the higher end, so the value per dollar has slipped.

Ranked #9 of 9 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 8 other providers we've modeled, in Cost-Efficiency Index order.

Pricing, states and verification reflect Henry Meds's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Henry Meds's site. Not medical advice; see our disclosure.

← Back to the value leaderboard